21 active trials 7 recruiting 2 Phase 3 16 sponsors
| Phase 1 | 2 | |
| Phase 2 | 8 | |
| Phase 3 | 2 | |
| Phase 4 | 1 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07264894 | ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a… | Zhengzhou University | Not Yet Recruiting | 2025-12-04 |
| Phase 3 | ||||
| NCT07377578 | A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With… | Guangzhou Lupeng Pharmaceutical Company LTD. | Recruiting | 2026-02-06 |
| NCT04662255 | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With… | Loxo Oncology, Inc. | Active, Not Recruiting | 2026-05-15 |
| Phase 2 | ||||
| NCT07416890 | Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1… | Zhejiang Cancer Hospital | Recruiting | 2026-02-18 |
| NCT06958705 | Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy | The First Affiliated Hospital with Nanjing Medical University | Recruiting | 2025-11-25 |
| NCT05833763 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With… | Australasian Leukaemia and Lymphoma Group | Recruiting | 2024-01-08 |
| NCT07526597 | Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK… | UNC Lineberger Comprehensive Cancer Center | Not Yet Recruiting | 2026-08-05 |
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody… | City of Hope Medical Center | Not Yet Recruiting | 2026-05-15 |
| NCT07122609 | Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without… | Ruijin Hospital | Not Yet Recruiting | 2025-08-14 |
| NCT06918015 | Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in… | Zhejiang Cancer Hospital | Not Yet Recruiting | 2025-04-15 |
| NCT06890585 | Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in… | Li Zhiming | Not Yet Recruiting | 2025-03-24 |
| Phase 1 | ||||
| NCT06675123 | Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With… | City of Hope Medical Center | Recruiting | 2026-08-05 |
| NCT07574073 | CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory… | Qi deng | Not Yet Recruiting | 2026-05-22 |
| Not applicable | ||||
| NCT07592481 | Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating… | Centre Hospitalier de la côte Basque | Not Yet Recruiting | 2026-06-22 |
| NCT06029166 | Subcutaneous Cardiac Monitoring of Patients With BTK Inhibitors | University Hospital, Caen | Not Yet Recruiting | 2023-09-08 |
| Not specified | ||||
| NCT05724121 | Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or… | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 2026-08-07 |
| NCT05506410 | A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed… | Zhengzhou University | Recruiting | 2022-08-18 |
| NCT06211413 | Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors | Abramson Cancer Center at Penn Medicine | Enrolling by Invitation | 2026-03-23 |
| NCT07283965 | Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With… | University Hospital, Caen | Not Yet Recruiting | 2025-12-16 |
| NCT06557304 | The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in… | Peking University People's Hospital | Not Yet Recruiting | 2024-08-21 |
| NCT06561243 | Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic… | University Hospital, Caen | Active, Not Recruiting | 2024-08-21 |
University Hospital, Caen (3) · City of Hope Medical Center (2) · Zhejiang Cancer Hospital (2) · Zhengzhou University (2) · Abramson Cancer Center at Penn Medicine (1) · Australasian Leukaemia and Lymphoma Group (1) · Centre Hospitalier de la côte Basque (1) · Guangzhou Lupeng Pharmaceutical Company LTD. (1) · Li Zhiming (1) · Loxo Oncology, Inc. (1)